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exceeding the FDA label recommendations of ADA 40 mg biweekly, ETN 50 mg 
weekly, and UST 45 mg every 12 weeks. RESULTS: In total, 15,400 PsA patients and 
40,545 PSO patients met the inclusion criteria. The number (proportion) of patients 
receiving increased maintenance doses for PsA was1,603 of 8,908 (18%) for ADA 
and 1,300 of 7,647 (17%) for ETN. The number (proportion) of patients receiving 
increased maintenance doses for PSO was 3,187 of 21,234 (15%) for ADA; 5,201 of 
16,318 (32%) for ETN; and 3,136 of 6,915 (45%) for UST. CONCLUSIONS: A large 
subgroup of patients treated with commonly used biologic agents is maintained 
on increased maintenance doses.
PMS87
PerSiStence With FirSt-Line BioLogicS USed in rheUMatoid arthritiS 
in a US Managed care PoPULation
Gu T.1, Shah N.2, Deshpande G.1, Tang D.H.2, Eisenberg D.1, Harrison D.J.2
1HealthCore Inc., Wilmington, DE, USA, 2Amgen Inc., Thousand Oaks, CA, USA
OBJECTIVES: To describe one-year persistence with first-line biologic treatments 
(abatacept [ABA], adalimumab [ADA], certolizumab [CER], etanercept [ETN], 
golimumab [GOL], and infliximab [INF]) in a US managed care population with 
rheumatoid arthritis (RA). METHODS: This is a retrospective cohort study using 
administrative data for individuals in HealthCore Integrated Research Database 
(HIRDSM). The study cohort included patients initiating first-line biologics between 
Jul 2009 and Jan 2013 and was followed for one year since biologic initiation. The 
first biologic used following 6 months of continuous enrollment defined the index 
event. Non-persistence was defined as the absence of persistence, which entails at 
least one > 45-day gap in days of supply on their index agent or a biologic switch. 
Non-persistent patients were further categorized as switching, having a non-index 
biologic claim prior to or following the first gap; restarting, having an index bio-
logic claim after the gap; or discontinuation, no claims for any biologic following 
the gap. RESULTS: A total of 4,937 patients met the eligibility criteria (ABA:290, 
ADA:1,471, CER:132, ETN:2,331, GOL:184, INF:529; mean age:48.4, 76.7% female). 
45.2%, 42.3%, 32.6%, 45.0%, 33.7% and 46.7% patients on ABA, ADA, CER, ETN, GOL, 
and INF were persistent, respectively. GOL patients were the least likely to either 
persist or restart therapy (49.5%), followed by CER (56.1%), ADA (60.4%), ABA (61.4%), 
ETN (63.1%), and INF (64.3%). Switching rate was lowest for ABA (13.1%) and high-
est for GOL (18.5%). Discontinuation rate was lowest for INF (19.7%) and highest for 
GOL (32.1%). CONCLUSIONS: Overall, less than half of patients with RA on first-line 
biologics were persistent during the first year of therapy in this population. As low 
persistence may compromise treatment effectiveness, more research is needed to 
understand the reasons for non-persistence.
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OBJECTIVES: To estimate the length of gaps in reimbursement when an etanercept 
patient transitions from private to public plans, and describe their treatment 
patterns and lines of therapy. METHODS: A retrospective cohort of medication 
transaction data (IMS Brogan Lifelink® database) from Ontario and Quebec phar-
macies was analyzed. Patients were eligible if their last etanercept transaction 
from a private plan (index date) was between 01/01/2010 and 06/30/2013 and their 
first transaction from a public plan was within one year from the index date. The 
gaps in reimbursement were the difference between the index date plus days’ 
supply and the date of the first public etanercept transaction. RESULTS: Of 474 
patients included, 432 continued a DMARD or biologic in their public plan and 
397 had at least 1 year of follow-up from their first public claim. Patients were 
50% from Ontario, 40% male. 73% had rheumatoid arthritis (RA) and 70% were < 
65 years. 75% had a gap in reimbursement (median = 19 days). 25% had either 
no gap, or an overlap in dispensed prescriptions, while 9% stopped their therapy 
altogether. Of patients who continued etanercept therapy on a public plan, 45% 
had a gap in coverage that would be considered a clinically meaningful delay in 
treatment (> 21 days). For etanercept patients who continued therapy for at least 
1 year, 71% progressed to etanercept ± DMARD, 5% to another biologic ± DMARD, 
and 23% to a DMARD only as their first line public therapy. CONCLUSIONS: 
A clinically significant number of patients experienced a meaningful gap in 
etanercept coverage which can result in suboptimal clinical outcomes. Over 
20% of patients revert back to DMARD therapy on a public plan even after pre-
viously receiving a biologic. Almost 10% do not continue RA treatment on a 
public plan.
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OBJECTIVES: i) to provide an overview of the new Common Drug Review (CDR) 
evaluative process for SEBs by the Canadian Agency for Drugs and Technologies in 
Health (CADTH); ii) to illustrate the Canadian Drug Expert Committee (CDEC) rec-
ommendation from the first monoclonal antibody SEB (infliximab SEB; Inflectra) 
in Canada and how the recommendation compares with regulatory approval; 
and iii) if possible (depending on timing of listings) to highlight how the public 
reimbursement of infliximab SEB compares with that of the reference infliximab 
(Remicade). METHODS: CDR’s SEB submission procedures were retrieved from 
CADTH’s website in order to delineate its history. The CDR recommendation of 
the infliximab SEB was compared to Health Canada’s approved indications. The 
pan-Canadian Pharmaceutical Alliance website was examined for the status of 
the infliximab SEB for potential negotiation. Formulary listing statuses and public 
reimbursement criteria are to be retrieved from provincial and federal formularies 
OBJECTIVES: To assess clinical characteristics of RA patients considered biosimilar-
infliximab-suitable (when it becomes available) by their physicians, in comparison 
to those who were not considered infliximab-biosimilar-suitable in EU. METHODS: 
A medical chart-review study of RA patients was conducted among physicians 
(primarily rheumatologists) in hospitals/private practices in UK/France/Germany/
Italy/Spain (5EU) to collect de-identified data on patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status; physicians identi-
fied whether patient was biosimilar-infliximab-suitable (yes/no), and if yes, rated 
how likely would they prescribe biosimilar-infliximab to them when the product 
becomes available. Physicians were screened for practice-duration and patient-
volume and recruited from a large panel to be geographically representative. 
Consecutive patients currently on (or discontinued within past-3mo) biologic visit-
ing each center/practice during the screening period were selected for chart abstrac-
tion; analysis compared biosimilar-infliximab-suitable to those who were not (per 
physician judgment), excluding those who previously failed infliximab. RESULTS: 
731 patients (UK:166/France:110/Germany:66/Italy:190/Spain:199) were included 
in the analysis. 260 (36%; UK:47%/France:27%/Germany:38%/Italy:40%/Spain:26%) 
were identified as biosimilar-infliximab-suitable; of these, 58% were rated > = 5 
(scale:7(extremely likely)-1(not at all likely)) regarding likelihood of being prescribed 
biosimilar-infliximab. For biosimilar-infliximab-suitable Yes/No groups, mean age: 
50.5yrs/ 50.9yrs; Female:74% (both-groups); time since diagnosis: 70.2/84.1mo; 
mean # of lines of past biologic/oral-DMARD use: 1.2/1.3. Current drug class usage 
included (biosimilar-infliximab-suitable:Yes/No): biological-DMARD:96%/93%, non-
biological-DMARD:60%/63%, steroids:21%/28%, NSAIDs-COX2-inhibitors:11%/7%, 
NSAIDs- non-COX2-inhibitors:16%/11%, and analgesics:25%/12%. Percentage 
patients with moderate/severe disease (per physician judgment; biosimilar-inf-
liximab-suitable:Yes/No):49%/41%. Among those with available data, recent lab/
disease measures were (biosimilar-infliximab-suitable:Yes/No): ESR(23.3/22.7mm/h) 
and CRP(14.2/8.0mg/dl); HAQ(1.0/1.0), DAS28 (3.2/3.0), VAS(0-10scale; 3.8/3.6), Swollen 
Joint Count(3.2/2.1) and Tender Joint Count(5.3/3.2). CONCLUSIONS: Patients con-
sidered infliximab-biosimilar-suitable (per clinical judgment) had been in care for 
relatively shorter period, had higher disease severity and a lower percentage of them 
used steroids. Physicians were also not readily prepared to prescribe the biosimilar 
to all infliximab-biosimilar-suitable patients. Further scrutiny is warranted to under-
stand the drivers behind physician perception of biosimilar-infliximab-suitability.
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OBJECTIVES: To examine biologic use, health care costs, and medication effectiveness 
for patients initiating biologic DMARDs before vs. after a 2012 policy change imple-
mentation restricting receipt of adalimumab to patients who had previously failed 
another biologic. METHODS: Patients newly initiating a biologic from 01JAN2011-
30JUN2012, and continuously enrolled for 1 year before and after the initial biologic 
claim (index) were identified from a large geographically diverse US health plan affili-
ated with Optum. Patients with a claim for rheumatoid arthritis (RA), psoriasis, pso-
riatic arthritis, or ankylosing spondylitis were included. Total health care costs were 
examined in the 1-year post-index for all patients. Medication effectiveness at 1-year 
was assessed in patients with RA using a previously validated claims-based algorithm. 
Cost and effectiveness were examined comparing patients initiating a biologic before 
vs. after policy implementation (01JAN2011-30JUN2011 vs. 01JAN2012-30JUN2012). 
Total health care costs were inflation-adjusted using the 2013 CPI, and biologic cost 
was calculated using December 2013 WAC values. RESULTS: Of 46,668 patients treated 
with a biologic from 01JAN2011-30JUN2012, 4,181 met all selection criteria; 1,441 
and 1,330 patients newly initiated a biologic before vs after policy implementation. 
Adalimumab and etanercept accounted for 40.2% and 41.3% of new starts in 2011, 
respectively. In 2012 19.5% and 51.4% initiated adalimumab and etanercept, respec-
tively. The 2011 vs 2012 mean [median] total health care costs were $10,941 [$4,821] 
vs. $10,467 [$4,558] (p= 0.59) and the overall cost of all biologics were $25,328 [$25,361] 
vs. $24,783 [$25,307] (p= 0.26). The percentage of RA patients effectively treated in the 
2011 and 2012 cohorts was 25.6% vs. 25.0%, respectively (p= 0.78). CONCLUSIONS: 
Policy implementation resulted in a noticeable change in the proportion of patients 
treated with adalimumab and etanercept. Patients initiating therapy before and after 
policy implementation experienced similar total health care costs, biologic cost, and 
algorithm-defined medication effectiveness.
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OBJECTIVES: Psoriasis (PSO) and psoriatic arthritis (PsA) are immune-mediated 
inflammatory diseases. Therapeutic management may include use of biologic 
agents such as adalimumab (ADA), etanercept (ETN), and ustekinumab (UST). In 
clinical practice, patients may receive increased doses during the maintenance 
phase of treatment, exceeding the dosing recommended in FDA labels. The objec-
tive of this study was to assess the proportion of patients treated with ADA or ETN 
for PsA, and ADA, ETN, or UST for PSO who receive an increased maintenance 
dose. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient diag-
noses of PsA or PSO were selected from the Symphony PTD Claims Database if 
their first biologic prescription date (index date) fell between May 2010 and April 
2013. Patients were included if (1) full access was available to all pharmacy claims 
≥ 12 months before and ≥ 12 months after their index date, and (2) they were 
treatment-naive to the agent of interest pre-index. Treatment with a different 
biologic pre-index was not considered a reason for exclusion. Dosing was assessed 
over 12 months post-index. Increased maintenance doses were defined as doses 
